Study of endostatin, tumstatin and PEDF, the natural angiogenesis inhibitors, potential in avasculargenic therapy

Purpose: To evaluate the potential of endostatin, tumstatin and PEDF in avasculargenic therapy.

Methods: The avasculargenic potential of the natural angiogenesis inhibitors was explored on the model of alkaline burn, attended with angiogenesis of cornea. The model was developed on 8 rabbits. The injections were performed in calculated and tenfold increased dose after the vascularization had been formed. The injections were made daily, subconjunctively. There were 10 injections in total. The animals were observed for three months.

Results: The clinical findings were obtained which prove the efficiency of the natural angiogenesis inhibitors in avasculargenic therapy. Tumstatin was registered as possessing the maximum clinically significant dose-dependent avasculargenic potential.

Conclusion: The avasculargenic potential of the natural angiogenesis inhibitors — endostatin, tumstatin and PEDF — in avasculargenic therapy has been experimentally explored. As a result there was obtained the evidence of the clinically significant dosedependent avasculargenic potential of tumstatin, the natural angiogenesis inhibitor.

1. Лихванцева В. Г., Арутюнян Е. В., Мирошников А. И., Есипов Р. С., Салихов А. Ю., Андреев Ю. В. и др. Изучение in vivo антиангиогенной активности природных ингибиторов ангиогенеза: эндостатина, тумстатина и PEDF // Офтальмохирургия. 2011. № 1. С. 76‑81.

2. Лихванцева В. Г., Арутюнян Е. В., Белоус О. В. VEGF-зависимая антиангиогенная терапия в офтальмологии // Офтальмохирургия. 2011. № 1. С. 82‑87.

3. Agnès Noël, Maud Jost, Vincent Lambert, et al. Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts// Trends Mol. Med. 2007. V. 13. P. 345‑352.

4. Apte, R. S. (2004) Stimulation of neovascularization by the anti-angiogenic factor PEDF // Invest. Ophthalmol. Vis. Sci. 2004. V. 45. P. 4491‑4497.

5. Atchaneeyasakul L. O., Davis E., Alsheikh O. J., et al. Lentiviral vector transfer of either tumstatin or tum — 4 gene fails to inhibit proliferation of ocular choroidal melanoma and retinoblastoma cell cultures // Invest Ophthalmol Vis Sci. 2005. V. 46. E-Abstract 4249.

6. Bouck N. PEDF: anti-angiogenic guardian of ocular function // Trends. Mol. Med.2002. V. 8. P. 330‑334.

7. Hajitou A., Grignet C., Devy L., et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells // FASEB J. 2002. V. 16. P. 1802‑1804.

8. Hajitou A., Sounni N. E., Devy L., et al. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis // Cancer Res. 2001. V. 61. P.3450‑3457.

9. Cai J., Jiang W., Grant M. B., et al. Pigment epithelium-derived factor (PEDF) inhibits angiogenesis via regulated intracellular proteolysis of VEGFR1 // J Biol Chem. 2006. V. 281. P. 3604‑3613.

10. Barnstable C. J., Tombran-Tink J. Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential // Progress in Retinal and Eye Res. 2004. V. 23. P. 561‑577. Переставить по алфавиту

11. Dawson D. W., Volpert O. V., Gillis P., et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis // Science. 1999. V. 285. P. 245‑248.

12. Developments in Ophthalmology. Anti-VEGF / Ed. F Bandello, M. Battaglia Parodi. KARGER, Basel-Freiburg-Paris-London, 2010. V. 46. P. 144.

13. Maeshima Y., Manfredi M., Reimer C., et al. Extracellular Matrix-derived Peptide Binds to Integrin and Inhibits Angiogenesis // J. Biol. Chem. 2001. V. 276. P. 15240‑15248.

14. Marneros A. G., Olsen B. R. The role of collagen-derived proteolytic fragments in angiogenesis // Matrix Biol. 2001. V. 20. P. 337‑345.

15. Marneros AG, Olsen BR.Age-dependent iris abnormalities in collagen XVIII / endostatin deficient mice with similarities to human pigment dispersion syndrome// Invest Ophthalmol Vis Sci. 2003. V.44. P. 2367‑2372.

16. Marneros A. G., Douglas R. K., Uwe H., et al. Collagen XVIII / endostatin is essential for vision and retinal pigment epithelial function // EMBO J. 2004. V. 23. P.89‑99.

17. Marneros A. G., Olsen B. R. Physiological role of collagen XVIII and endostatin //FASEB J. 2005. V. 19. P. 716‑728.

18. National Academy of Sciences. Guide for the Care and Use of Laboratory Animals.— Washington, DC: National Academy Press, 1996. Р. 274

19. Sertie, A. L., Sossi V., Camargo A. A., Zatz M., Brahe C., Passos-Bueno M. R. Collagen XVIII, containing an endogenous inhibitor of angiogenesis and tumor growth, plays a critical role in the maintenance of retinal structure and in neural tube closure // Hum. Mol. Genet. 2000. V. 9. P. 2051‑2058.